Bottom line
About 40% of initial GLP-1 prior authorization denials are overturned on appeal, and the number is higher when appeals include peer-to-peer physician review. The right appeal depends on the denial reason, which is usually one of five categories.
This guide walks through the full appeal process: reading your denial letter correctly, identifying the winning argument, building the documentation packet, and escalating through the formal levels.
First: read your denial letter correctly
Your denial letter will cite a specific reason. Common ones:
1. "Not medically necessary" — generally means the documentation didn't meet the plan's clinical criteria. 2. "Step therapy required" — you need to try a cheaper drug first. 3. "Not on formulary" — the specific drug isn't covered; an alternative might be. 4. "Quantity limit exceeded" — usually a dose too high for the plan's criteria. 5. "Experimental / investigational" — off-label use, or the drug isn't FDA-approved for your indication.
Each category has a different winning appeal strategy. The denial letter will also cite the plan's clinical policy number — save this; you'll need it.
Step 1: Understand the winning argument
"Not medically necessary" denials are usually won by submitting better documentation of: BMI at or above threshold, at least one weight-related comorbidity, documented prior weight-loss attempts, and a prescriber attestation.
"Step therapy" denials are won by either trying the required step (usually metformin or an older weight-loss drug) for the minimum duration, OR documenting why you can't (contraindication, prior failure, intolerance).
"Not on formulary" denials are won by: (a) switching to a covered alternative (Wegovy instead of Zepbound, or vice versa), or (b) requesting a formulary exception with medical justification.
"Quantity limit" denials are won by documenting the clinical rationale for the higher dose with BMI, prior response, and expected trajectory.
"Experimental" denials are the hardest — usually for off-label use. Best move is typically to pivot to an on-label alternative rather than appeal.
Step 2: Gather your documentation
The packet you need varies by denial type, but the core is usually:
- Signed letter from your prescriber attesting to medical necessity
- Current BMI with recent measurement date
- ICD-10 codes for obesity (E66.01–E66.9) plus any comorbidities
- Documented prior weight-loss attempts (diet/exercise programs,
prior medications tried and duration)
- Any relevant labs (HbA1c for prediabetes/diabetes, lipid panel,
TSH if thyroid issues)
- Justification for the specific drug requested (e.g., why Zepbound
over Wegovy)
For "step therapy" denials, add documentation of: the required step (if tried), or contraindications / intolerances (if not).
Step 3: File the first-level appeal
Every insurance plan has a first-level appeal process. You have 30–180 days from the denial to file (check your letter — plans differ).
The appeal typically goes to:
- The plan's medical director or pharmacy committee
- A review within 30 days (15 for urgent cases)
What to submit:
- Cover letter citing the denial reason and your counter-argument
- The documentation packet above
- A copy of the original denial letter
- Your prescriber's attestation
Where to submit: the address on the denial letter. Most plans accept online submission through the member portal now.
Step 4: Request peer-to-peer review
This is the single highest-yield step most patients skip.
In a peer-to-peer (P2P) review, your prescriber speaks directly with the plan's medical director (usually by phone, 10–15 minutes). Your prescriber presents the clinical case; the medical director asks questions.
P2P reviews overturn about 40% of initial denials for obesity drugs. Some programs that specialize in GLP-1 prescribing (Mochi Health, Form Health, MyStart Health) do P2Ps routinely and their success rates exceed 60% at some plans.
To request: your prescriber calls the PA phone number on the denial letter and asks for peer-to-peer. Most plans require scheduling within 7–10 days of the denial.
Step 5: Escalate to external review (if needed)
If first-level appeal and P2P both fail, you have the right to an external review through an Independent Review Organization (IRO). This is a state-regulated process; the IRO is not affiliated with your insurance company.
External review:
- Must be requested within 4 months of final denial (varies by
state)
- Free in most states
- Decision is legally binding on the insurance plan
- Overturns about 30–50% of denials that reach this stage
Your denial letter or member portal will explain the external review process specific to your plan and state.
Step 6: State insurance commissioner (last resort)
For denials that violate state law (e.g., a state that mandates obesity drug coverage and the plan violates it), you can file a complaint with your state insurance commissioner.
This is rarely the fastest path — external review usually resolves cases. But for patterns of denial or plan behavior that seems improper, the commissioner has regulatory authority.
What NOT to do
- Don't give up after the first denial. 40% overturn rate on
appeal is real.
- Don't self-appeal without prescriber support. Patient-only
appeals are less successful than prescriber-supported ones.
- Don't miss the deadline. 30–180 days from denial; check your
specific plan.
- Don't pay out-of-pocket while appealing unless your prescriber
specifically advises bridging — retroactive reimbursement is inconsistent.
Common denial scenarios and the winning move
Zepbound denied because "Wegovy is preferred." → Either switch to Wegovy, or appeal citing efficacy data from SURMOUNT-5 showing tirzepatide's superiority and clinical rationale for tirzepatide specifically.
Wegovy denied because "BMI not documented within 6 months." → Get a current BMI measured, resubmit. Often approved on first appeal.
GLP-1 denied for weight loss when on Medicare. → Medicare Part D statutorily excludes weight-loss drugs. Pivot to Wegovy under the cardiovascular risk reduction indication if you have established CVD. See our coverage guide.
Step therapy requires metformin trial first. → Either try metformin for the minimum duration (usually 3 months), or document contraindication/intolerance if you can't.
Quantity limit caps at 10 mg tirzepatide. → Submit appeal with clinical justification for 15 mg (usually BMI and prior response data).
What programs handle this best
Insurance navigation is a real specialty. The programs we've benchmarked as strongest:
- Mochi Health — general commercial PAs
- MyStart Health — Medicaid, Medicare
Advantage, employer self-funded
- Form Health — complex clinical cases
- PlushCare — broad commercial + Medicare
Advantage
If you've been denied at a non-specialist program, switching to one of the above for the appeal alone is often worth it.